



UPDATED INVESTOR PRESENTATION

SEPTEMBER 2018

ASX: ZLD

OTCQB: ZLDAF

WWW.ZELDATHERAPEUTICS.COM



DISCLAIMER & IMPORTANT NOTICE

Disclaimer

This presentation has been prepared by Zelda Therapeutics Ltd ACN 103 782 378 (“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.

No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.

Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.



CORPORATE VISION

OUR VISION

- Become a global leader in clinical validation of medicinal cannabis and rapid delivery of transformative medicines to patients.

OUR STRATEGY

- Singular focus on clinical trials that address unmet needs of patients and clinicians for clinically validated cannabis medicines.
- Generate novel IP, with a particular focus on cancer, and establish distribution partnerships to rapidly access global cannabis markets.



OVERVIEW

ZELDA THERAPEUTICS OFFERS INVESTORS EXPOSURE TO A WORLD-CLASS TEAM AT VERY ATTRACTIVE VALUATIONS
AND WITH SIGNIFICANT VALUATION DRIVERS OVER THE NEXT 12-18 MONTHS

GLOBALLY EXPANDING INDUSTRY

Medical cannabis is one of the world's fastest growing industries with increasing acceptance and regulatory approvals globally.

MEDICINAL FOCUS

Focused solely on generating rigorous clinical and pre-clinical data in a range of indications.

TARGETTING ATTRACTIVE MARKETS

Building a portfolio of activities in cancer, insomnia, autism and other projects pending.

CLEAR PATH TO COMMERCIALISATION

Multiple revenue opportunities to license and generate milestone and royalty payments.

INDUSTRY RECOGNISED BOARD & MANAGEMENT TEAM AND GLOBAL PLARTNERSHIPS

Seasoned executives & advisors with extensive research, pharma & capital markets track records.

GENERATING NOVEL INTELLECTUAL PROPERTY

Multiple patent families including prognostics, combination therapies & composition of matter.

ATTRACTIVE INVESTMENT FUNDAMENTALS

Compared to other clinical stage biotechs and medical cannabis companies.



CORPORATE SNAPSHOT

HISTORY

- Focussed on clinical validation and rapid delivery of medicinal cannabis therapies to market.
- Founded in August 2015 and listed on ASX November 2016.
- Access to US patient data informs clinical development.
- Experienced pharma and cannabis management team.
- Path to revenue facilitated by strategic IP, novel products and global distribution partnerships.

FINANCIALS (as at 20 Sep 2018)

	AUD\$
• Share Price	\$0.072
• 52w Range	\$0.067 - 0.16
• 4w Trading Volume	1.05m
• Shares on Issue	755m
• Market Capitalisation	\$54m
• Cash (June, 2018)	\$5.78m
• Cash Burn (2018 FY)	\$1.73m
• Debt	\$0
• CannPal options (@20c)	7.25m

SHARE PRICE (as at 20 Sep 2018)




CAPITAL STRUCTURE

Top 20 Shareholders: 45%
Listed Options: 40m

Top 5 Shareholders

• Mara Gordon	10.5%
• Jason Peterson	10.0%
• Harry Karelis	6.6%
• Stewart Washer	4.7%
• Amit Gupta	2.2%



BOARD & MANAGEMENT



Dr Richard Hopkins
Managing Director

Richard is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies.



Harry Karelis
Founder & Executive Chairman

Harry is a co-founder of Jindalee Partners and has in excess of 25 years diversified experience in the financial services sector including specialist med-tech private equity investing.



Dr Stewart Washer
Founder & Director

Stewart has 25 years of CEO and Board experience in medical/biotech. He is currently Chairman of Orthocell Ltd and Director of Cynata Ltd.



Mara Gordon
Founder & Director

Mara specialises in the development of cannabis extract treatment protocols for seriously ill patients in California.



Jason Peterson
Founder & Director

Jason is a Director, major shareholder and Head of Corporate at boutique stock broking and investment banking firm, CPS Capital. He has more than 21 years of experience in the financial advisory sector.



MEDICAL ADVISORY TEAM



Professor Manuel Guzman

Professor of Biochemistry and Molecular Biology at Madrid's Complutense University and expert on the molecular mechanisms of action and role of cannabinoids in controlling cell generation and death.



Dr Cristina Sanchez

Assistant Professor at Complutense University, Madrid Spain. Specialist in the area of lipid signaling, including cannabinoids in an oncology setting.



Dr Noah Federman

Paediatric clinical and research oncologist. Director of the Paediatric Bone and Soft Tissue Sarcoma Program at University of California, part of the prestigious UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Centre.



Dr David Casarett

Professor of Medicine and a leading palliative care physician at Duke University School of Medicine. Clinical interests include use of cannabis to treat pain and nausea.




Dr Dustin Sulak

Dustin Sulak is an integrative medicine practitioner and leader in the emerging field of cannabinoid medicine. Founder of two specialist clinics in the US that have treated over 18,000 patients with medical cannabis.



MILESTONES ACHIEVED



STRATEGIC PARTNERSHIPS



Manufacturing and distribution partner for Zelda products in Germany



Autism Clinical Trial



THE UNIVERSITY OF
WESTERN AUSTRALIA

Insomnia trial with world leading Sleep Centre



Australian animal health company developing medicinal cannabis products for animal markets. Zelda has options over ~7% of CannPal.



Pancreatic cancer and cognitive decline



Paediatric brain cancer



Breast cancer



HOW ARE WE DIFFERENT?




STRATEGIC FOCUS ON RAPIDLY GROWING MEDICINAL CANNABIS SECTOR

- Global Medicinal Cannabis Market worth \$12 billion in 2018¹.
- Forecast to grow to \$40-55 billion 2028^{1,2} (18% CAGR).
- ~ 1% of populations in US and Canada already using medicinal cannabis.
- Zelda targeting prescription-based **medicinal cannabis** sector which is growing at 80% pa.²


1. <https://www.persistencemarketresearch.com/market-research/medical-marijuana-market.asp>

2. European Cannabis Report – 3rd Edition (Prohibition Partners)


3. European Cannabis – Cannacord Report 31st August, 2018



Relative MC market share in Europe³



STRATEGIC FOCUS ON WHOLE-PLANT EXTRACTS AND “ENTOURAGE EFFECT”



1. Market approved: Sativax, Epidiolex, Nabilone, Dronabinol

FOCUS ON EMERGING LARGE PATIENT MARKETS

BREAST CANCER

Most common cancer in women with > 2 million new cases diagnosed each year

PANCREATIC CANCER

12th most common cancer globally with very poor prognosis (<4% 5yr survival rates)

BRAIN CANCER

Common cancer with low survival rates



INSOMNIA

Insomnia affects approx. 35% of adults



AUTISM

Affects 1% people worldwide.



DIABETES COGNITIVE DECLINE

Diabetes a major risk factor for dementia which affects 50 million people worldwide




ACTIVE INTELLECTUAL PROPERTY STRATEGY

- Working with Australia’s leading patent attorney firm.
- Seven patent families filed:
 - Cancer
 - Skin Disease (topical)
 - Sleep Disorders
 - Cancer diagnostics
 - Autism
 - Anxiety
 - Opioid Reduction
- Patents provide protection until 2036.
- Generating novel IP is core to Zelda’s commercialisation strategy.
- IP will be essential as patent landscape becomes increasingly sophisticated and litigious.


Patent	Priority Date	Filing
Cancer	August 2016	WO2018/023166
Skin Disease	August 2016	WO2018/023164
Sleep Disorders	August 2016	WO 2018/023163
Insomnia	November 2017	AU2017904818
Cancer Prognosis	October 2016	WO 2018/071986 A1
Autism	September 2017	AU2017903766




PRECLINICAL: STRATEGIC FOCUS ON CANCER TO GENERATE NOVEL IP



COMMERCIALISATION MODEL



COMPARATIVE ANALYSIS



Company	Market Capitalisation ¹	Focus
Zelda Therapeutics (ASX:ZLD)	AUD \$54m	Research: Insomnia, Cancers, Autism and Skin disorders
AusCann (ASX:AC8)	AUD\$300m	Grow & Manufacture: Chronic and Neuropathic Pain Control
CANN Group (ASX:CAN)	AUD\$385m	Grow & Manufacture
Canopy Growth Corporation (TSX:WEED)	CAD\$14.5bn	Grow & Manufacture: Medical & Recreational
GW Pharmaceuticals (NASDAQ:GWPH)	US\$3.9bn	Research: Sativex (MS spasticity), Epidiolex (childhood epilepsy)

1. 20th September 2018



UPCOMING ACTIVITY & MILESTONE PIPELINE

BREAST CANCER

Follow-on studies focused on *in vivo* testing in conjunction with chemotherapy.

AUTISM

Recruitment for observational trial commenced.




BRAIN CANCER

Preclinical studies underway with initial results expected 2019.



PANCREATIC CANCER

Research programme commenced with animal data expected 4Q, 2018.



SLEEP DISORDER

Clinical trials commenced in Q3, 2018 with trial data expected by mid-2019.



STRONG STRATEGIC POSITIONING



- Global early mover in the medical space.
- Ongoing establishment of research collaborations with leading global institutions.
- Global strategic partnerships in place covering supply, manufacture and distribution.
- Dynamic intellectual property strategy including blocking patent activities.
- Diversified clinical pipeline – multiple shots on goal.
- Pre-clinical pipeline generating dossiers in the form big pharma and regulators expect.
- High level of sector M& A activity.
- Relatively low valuations compared to global peers suggests significant potential for value creation.
- Current research pipeline fully funded.
- Positioned for rapid entry into commercialisation phase upon successful clinical trials .



CONTACT US



@ZELDATHERAPEUTICS

WWW.ZELDATHERAPEUTICS.COM

Dr Richard Hopkins
Managing Director and CEO

AUSTRALIA

Level 26

140 St Georges Tce

Perth WA 6000

+61 413 056 628

rhopkins@zeldatherapeutics.com



APPENDIX



CLINICAL

AUTISM | POSITIVE OBSERVATIONAL STUDY



THE UNIVERSITY OF
WESTERN AUSTRALIA



- Observational study in Chile, demonstrated **successful results for treating core symptoms of autism.**



- Results were presented at the prestigious 23rd **World Congress of Neurology** in Kyoto, Japan.



- Results demonstrate cannabis extracts **were more effective than conventional autism medicines.**



- **71.4%** showed significant improvements in **at least one core symptom** and **66.7%** of treated patients showed significant **general overall improvement.**



- Successful clinical trial results will lead to product registration and distribution in global markets.



CLINICAL

INSOMNIA



- Insomnia affects approximately 35% of adults.



Current Insomnia treatment

- Benzodiazepines are tranquilisers usually prescribed for anxiety and insomnia.
- Overdoses from these cause almost 3 times more deaths than heroin & methamphetamine combined.



Zelda's Insomnia Trials

- Approved to conduct clinical trial with University of Western Australia Sleep Centre.
- Trial expected to commence in 2H-2018.



PRE-CLINICAL

BREAST CANCER



- **Zelda's plant-derived THC formulations** shown to have anti-cancer effect against a range of breast cancers, including triple negative, which is the most lethal form.



- Zelda's THC-rich formulation have greater anti-cancer effect than synthetic THC across all cancer subtypes, = **Entourage Effect!**



- Zelda's collaborators first to describe this **novel 'Entourage Effect'** in cell lines and **animal models of breast cancer.**



- Zelda's THC-rich formulation shown to improve potency of front-line cancer drugs.



- Supports use of plant-derived cannabinoid therapies to treat breast cancer types including **hormone receptor positive, HER2+ and Triple Negative cancer types.**



PRE-CLINICAL

PANCREATIC CANCER



- 12th most common cancer. Very poor prognosis with 1 year survival rates <20%. **Urgent need for new therapies and biomarkers to facilitate early diagnosis.**



- Collaborator published data showing **novel combination of CBD and gemcitabine** improves survival rates by **3-fold** using **gold standard mouse model** of pancreatic cancer.



- Expanded animal studies with Zelda currently ongoing . Assessing novel combinations of cannabinoids plus front-line cancer therapies for improved efficacy.



- If successful, Zelda aiming to progress to clinical trial in 2019. Have engaged leading clinical oncology team at a major Perth hospital.



- Progressing novel biomarker project, which has potential to address need for early diagnosis of pancreatic cancer.



PRE-CLINICAL

PAEDIATRIC BRAIN CANCER



- Medulloblastoma is **the most common malignant brain tumour in children**¹. Clinical evidence supports the use of cannabinoids to treat glioblastoma.



- Collaboration with world leading Brain Cancer team from Telethon Kids Institute with expertise in oncology and paediatric clinic trials.



- Initial results show **cannabinoids** inhibit the growth of brain cancer cells (Medulloblastoma) and also improve the anti-cancer activity of conventional radio-therapy.



- Animal studies focussing on use of cannabinoids in combination with front-line therapy and radiotherapy.

¹ John Hopkins Medicine. 2018. Neurology and Neuroscience: www.hopkinsmedicine.org



PRE-CLINICAL

DIABETES RELATED COGNITIVE DECLINE



- Diabetes **is a chronic disease that can lead to a number of complications including the damage to blood vessels in the brain**, associated with cognitive decline that can lead to dementia and other related conditions.



- Zelda's **research study will occur in well validated animal models** of diabetic cognitive decline developed by Curtin University.



- Zelda's **research to focus on studying the effect of a cannabinoid-based therapeutic** moderating the effects of cerebral capillary damage associated with diabetes.



- Potential to demonstrate that **daily dosing of certain cannabinoids can provide some type of long term benefit to diabetes sufferers** and moderate the effect of capillary damage.

